Linguamatics, a provider in enterprise text mining for the life science and other markets, recently announced that AstraZeneca, a customer of Linguamatics since 2003, has extended its license to the I2E semantic knowledge-discovery platform with a further multi-year deal. I2E provides flexible and scalable enterprise text mining within AstraZeneca's knowledge engineering strategy, and supports decision making at many points in the drug discovery process, including target selection, biomarker discovery and safety/toxicology. Financial details of the agreement were not disclosed.

"AstraZeneca's researchers need efficient access to relevant biomedical knowledge," commented Roger Hale, COO and Cofounder of Linguamatics. "I2E uses agile NLP-based text mining technology to provide high quality insights from literature sources in real-time, supporting key decisions with the right information at the right time."

To read full press release, click here. 

This BeyeNETWORK news item contains information from a recent press release by the company mentioned.